Ralph Link
34 Papers
117 Citations
Ralph Link is an academic researcher. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 7, co-authored 29 publications.
Chat about Author
Papers
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
Th Witthöft,Bernd Möller,K. H. Wiedmann,St Mauss,Ralph Link,J. Lohmeyer,M. Lafrenz,C. Gelbmann,Dietrich Hüppe,Claus Niederau,Ulrich Alshuth +10 more
TL;DR: This investigation confirms the well‐known risk–benefit ratio found in controlled studies in a clinical practice setting and shows the highest incidence of adverse events in the first 12 weeks of treatment.
65
Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.
Markus Cornberg,Jörg Petersen,Andreas Schober,Stefan Mauss,K Böker,Ralph Link,Rainer Günther,Y. Serfert,H Pfeiffer-Vornkahl,Michael P. Manns,Christoph Sarrazin,Dietrich Hüppe,Thomas Berg,Claus Niederau +13 more
TL;DR: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes, and several new treatment regimens have been approved but sometimes based on limited data.
47
Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA
Benjamin Heidrich,Steffen B. Wiegand,Peter Buggisch,Holger Hinrichsen,Ralph Link,Bernd Möller,Klaus H.W. Böker,Gerlinde Teuber,Hartwig Klinker,Elmar Zehnter,U Naumann,HW Busch,Benjamin Maasoumy,Undine Baum,Svenja Hardtke,Michael P. Manns,Heiner Wedemeyer,Jörg Petersen,Markus Cornberg +18 more
TL;DR: Treatment with PegIFN/RBV in a real world setting can be highly effective yet similar effective than PegIFn± sofosbuvir/ RBV in well-selected naïve G2/3 patients.
Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
Jona T. Stahmeyer,Siegbert Rossol,Florian Bert,Klaus H.W. Böker,Harald Robert Bruch,Christoph Eisenbach,Ralph Link,Christine John,Stefan Mauss,Renate Heyne,Eckart Schott,H Pfeiffer-Vornkahl,Dietrich Hüppe,Christian Krauth +13 more
TL;DR: This study is one of few investigating both, outcomes and costs, of treating HCV in a real-life setting and can serve as a reference in the discussion of increasing costs in recently introduced agents.
840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY
T. Witthoeft,Dietrich Hueppe,Christine John,J. Goelz,U Meyer,Renate Heyne,B. Moeller,Ralph Link,Gerlinde Teuber,S. Sworszt,A. Herrmann,A. Wollschlaeger,Axel Baumgarten,Karl-Georg Simon,H.-J. Cordes,G. Moog,Nektarios Dikopoulos,Stefan Mauss +17 more
16